Janux Therapeutics Q2 net loss $6.2M; cash $394.2M post $222.9M IPO

Janux Therapeutics, Inc.

2022-Q2 EPS reported -$1.52 revenue$862,000

Completed $222.9M IPO in June and $125.0M Series B in April, total $347.9M in quarter.
Cash and short-term investments of $394.2M at June 30, 2021 vs $7.8M at Dec 31, 2020.
Q2 net loss of $6.2M, compared to $2.5M in same period 2020; R&D expense $4.7M.
On track to submit at least two INDs by end of 2022 for lead TRACTr programs.
Appointed Shahram Salek-Ardakani as CSO and Wayne Godfrey as CMO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.